Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 18/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.50 |
| ▸ | TACR2 | P21452 | 1/20 | 0.40 |
| ▸ | IDH1 | O75874 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3635360 | 0.88 | P2RX3 (0.48) | P2RX3CYP2C9TACR2 | |
| SCHEMBL4240096 | 0.84 | P2RX3 (0.60) | P2RX3CYP2C9TACR2 | |
| SCHEMBL4231172 | 0.83 | P2RX3 (0.69) | P2RX3CYP2C9TACR2 | |
| SCHEMBL4225050 | 0.83 | P2RX3 (0.53) | P2RX3CYP2C9TACR2 | |
| SCHEMBL4230424 | 0.81 | P2RX3 (0.59) | P2RX3CYP2C9TACR2 | |
| SCHEMBL3668159 | 0.81 | P2RX3 (0.73) | P2RX3CYP2C9 | |
| SCHEMBL3635398 | 0.80 | P2RX3 (0.58) | P2RX3CYP2C9TACR2IDH1 | |
| SCHEMBL3638828 | 0.78 | P2RX3 (0.56) | P2RX3CYP2C9TACR2 | |
| SCHEMBL3641898 | 0.77 | P2RX3 (0.41) | P2RX3CYP2C9TACR2 | |
| SCHEMBL3639384 | 0.75 | P2RX3 (0.54) | P2RX3CYP2C9TACR2IDH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090099195-A1 | Therapeutic Compounds 570 | ASTRAZENECA AB (SE) | 2009-04-16 | — | — | US | disclosed |
| US-20090099195-A1 | Therapeutic Compounds 570 | ASTRAZENECA AB (SE) | 2009-04-16 | — | — | US | disclosed |
| US-20090099195-A1 | Therapeutic Compounds 570 | ASTRAZENECA AB (SE) | 2009-04-16 | — | — | US | disclosed |
| WO-2008136756-A1 | PYRROLOPYRIMIDIN-7-ONE DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | ASTRAZENECA AB (SE) | 2008-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099195-A1 | Therapeutic Compounds 570 | OPRL1, OPRK1, OPRM1 | P2RX3 53/4885CYP2C9 172/4885TACR2 158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.